CAS NO: | 1228108-65-3 |
规格: | ≥98% |
包装 | 价格(元) |
2mg | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
Molecular Weight (MW) | 700.78 |
---|---|
Formula | C42H40N2O8 |
CAS No. | 1228108-65-3 |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Solubility (In vitro) | DMSO: 100 mg/mL (142.7 mM) |
Water: <1 mg/mL (slightly soluble or insoluble) | |
Ethanol: 54 mg/mL (77 mM) | |
Synonyms | BI-97C1; BI 97C1; BI97C1 |
General | BI-97C1 displays in vivo efficacy in transgenic mice in which Bcl-2 is overexpressed in splenic B-cells and also demonstrates superior single-agent antitumor efficacy in a prostate cancer mouse xenograft model that depends on Mcl-1 for survival |
---|---|
Animal model | Bcl-2 transgenic mice, human prostate cancer xenografts |
Formulation | Ethanol:Cremophor EL:saline = 10:10:80 |
Dosages | 1 , 3, 5 mg/kg |
Administration | intraperitoneally |
Reference | [1] Wei J, et al. J Med Chem, 2010, 53(10), 4166-4176 |
The combination regimen of Sabutoclax and Celecoxib inhibits OSCC tumor growth in athymic nude mice. Oncotarget 6(18):16623-37, 2015 | Genetic or pharmacological knockdown of Mcl-1 sensitizes PC to mda-7/IL-24–mediated apoptosis. PNAS, 108 (21), 8785–8790, 2011 |